TFF Pharmaceuticals said that it has received a notice of allowance for US Patent Application No. 12/778,795, titled, “Compositions and Methods of Making Brittle-Matrix Particles Through Blister Pack Freezing,” which covers technology related to the company’s DPI products for respiratory conditions.
According to the company, the TFF technology has been used to create dry powder formulations of small molecules and biologics that are in development for diseases such as asthma, COPD, and lung infections.
TFF Pharmaceuticals CEO Glenn Mattes commented, “We are pleased to receive this key patent approval which secures the protection of our novel drug delivery system for years and will mean a significant competitive advantage. It is an important milestone in moving forward with commercializing a suite of drug products in development. The patent represents further validation of our proprietary thin film freezing technology. It expands our already extensive intellectual property portfolio of more than 30 patents. This is another progress step toward providing safer and more effective dry powder inhalation drug delivery options to benefit the global health community.”
University of Texas Professor Robert O. (Bill) Williams III, who developed the process, said, “The new patent is a foundational patent for TFF Pharmaceutical’s novel delivery system of dry powder drugs for inhalation of both biologic and small molecule drugs, allowing multiple opportunities to develop advanced drug products in a way not currently available. The patent complements and extends the company’s IP. It will enable TFF to leverage broad applications of the innovative technology for commercialization, providing alleviation of suffering and improved therapeutic outcomes for patients with serious lung diseases and conditions.”
Read the TFF Pharmaceuticals press release.
